297 related articles for article (PubMed ID: 24319187)
1. Therapeutic applications: natural killer cells in the clinic.
Miller JS
Hematology Am Soc Hematol Educ Program; 2013; 2013():247-53. PubMed ID: 24319187
[TBL] [Abstract][Full Text] [Related]
2. NK cells in therapy of cancer.
Bachanova V; Miller JS
Crit Rev Oncog; 2014; 19(1-2):133-41. PubMed ID: 24941379
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of natural killer cells in cancer therapy and transplantation.
Knorr DA; Bachanova V; Verneris MR; Miller JS
Semin Immunol; 2014 Apr; 26(2):161-72. PubMed ID: 24618042
[TBL] [Abstract][Full Text] [Related]
4. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.
Vallera DA; Felices M; McElmurry R; McCullar V; Zhou X; Schmohl JU; Zhang B; Lenvik AJ; Panoskaltsis-Mortari A; Verneris MR; Tolar J; Cooley S; Weisdorf DJ; Blazar BR; Miller JS
Clin Cancer Res; 2016 Jul; 22(14):3440-50. PubMed ID: 26847056
[TBL] [Abstract][Full Text] [Related]
5. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA
J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394
[TBL] [Abstract][Full Text] [Related]
6. Current strategies exploiting NK-cell therapy to treat haematologic malignancies.
Johnson JK; Miller JS
Int J Immunogenet; 2018 Jul; ():. PubMed ID: 30009514
[TBL] [Abstract][Full Text] [Related]
7. An Uncoupling of Canonical Phenotypic Markers and Functional Potency of
Lieberman NAP; DeGolier K; Haberthur K; Chinn H; Moyes KW; Bouchlaka MN; Walker KL; Capitini CM; Crane CA
Front Immunol; 2018; 9():150. PubMed ID: 29456538
[TBL] [Abstract][Full Text] [Related]
8. Licensed human natural killer cells aid dendritic cell maturation via TNFSF14/LIGHT.
Holmes TD; Wilson EB; Black EV; Benest AV; Vaz C; Tan B; Tanavde VM; Cook GP
Proc Natl Acad Sci U S A; 2014 Dec; 111(52):E5688-96. PubMed ID: 25512551
[TBL] [Abstract][Full Text] [Related]
9. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.
Wiernik A; Foley B; Zhang B; Verneris MR; Warlick E; Gleason MK; Ross JA; Luo X; Weisdorf DJ; Walcheck B; Vallera DA; Miller JS
Clin Cancer Res; 2013 Jul; 19(14):3844-55. PubMed ID: 23690482
[TBL] [Abstract][Full Text] [Related]
10. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.
Gleason MK; Verneris MR; Todhunter DA; Zhang B; McCullar V; Zhou SX; Panoskaltsis-Mortari A; Weiner LM; Vallera DA; Miller JS
Mol Cancer Ther; 2012 Dec; 11(12):2674-84. PubMed ID: 23075808
[TBL] [Abstract][Full Text] [Related]
11. Role of CD16 (Fc receptor III) and interleukin-2 in the reactivation of natural killer cells after inhibitory target cell contact.
Heiskala M; Ståhls A; Seppälä I; Timonen T
Nat Immun Cell Growth Regul; 1991; 10(5):265-77. PubMed ID: 1836835
[TBL] [Abstract][Full Text] [Related]
12. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
13. Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells.
Williams RL; Cooley S; Bachanova V; Blazar BR; Weisdorf DJ; Miller JS; Verneris MR
Biol Blood Marrow Transplant; 2018 Mar; 24(3):618-622. PubMed ID: 29197679
[TBL] [Abstract][Full Text] [Related]
14. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.
Bachanova V; Cooley S; Defor TE; Verneris MR; Zhang B; McKenna DH; Curtsinger J; Panoskaltsis-Mortari A; Lewis D; Hippen K; McGlave P; Weisdorf DJ; Blazar BR; Miller JS
Blood; 2014 Jun; 123(25):3855-63. PubMed ID: 24719405
[TBL] [Abstract][Full Text] [Related]
15. The anti-tumor role of NK cells in vivo pre-activated and re-stimulated by interleukins in acute lymphoblastic leukemia.
Jin F; Lin H; Gao S; Hu Z; Zuo S; Sun L; Jin C; Li W; Yang Y
Oncotarget; 2016 Nov; 7(48):79187-79202. PubMed ID: 27816971
[TBL] [Abstract][Full Text] [Related]
16. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
Wu Z; Xu Y
J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
[TBL] [Abstract][Full Text] [Related]
17. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation.
Koehl U; Sörensen J; Esser R; Zimmermann S; Grüttner HP; Tonn T; Seidl C; Seifried E; Klingebiel T; Schwabe D
Blood Cells Mol Dis; 2004; 33(3):261-6. PubMed ID: 15528141
[TBL] [Abstract][Full Text] [Related]
18. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.
Torelli GF; Guarini A; Maggio R; Alfieri C; Vitale A; Foà R
Haematologica; 2005 Jun; 90(6):785-92. PubMed ID: 15951291
[TBL] [Abstract][Full Text] [Related]
19. IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion.
Huenecke S; Zimmermann SY; Kloess S; Esser R; Brinkmann A; Tramsen L; Koenig M; Erben S; Seidl C; Tonn T; Eggert A; Schramm A; Bader P; Klingebiel T; Lehrnbecher T; Passweg JR; Soerensen J; Schwabe D; Koehl U
J Immunother; 2010; 33(2):200-10. PubMed ID: 20145545
[TBL] [Abstract][Full Text] [Related]
20. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.
Berrien-Elliott MM; Becker-Hapak M; Cashen AF; Jacobs M; Wong P; Foster M; McClain E; Desai S; Pence P; Cooley S; Brunstein C; Gao F; Abboud CN; Uy GL; Westervelt P; Jacoby MA; Pusic I; Stockerl-Goldstein KE; Schroeder MA; DiPersio JF; Soon-Shiong P; Miller JS; Fehniger TA
Blood; 2022 Feb; 139(8):1177-1183. PubMed ID: 34797911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
